Skip to main content
Download PDF

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

Acta Neuropathologica Communications volume 11, Article number: 119 (2023) Cite this article

Abstract

Post-translational modifications to the carboxyl (C) terminus domain of α-synuclein can play an important role in promoting the pathologic aggregation of α-synuclein. Various cleavages that diminish this highly charged, proline-rich region can result in exposure of hydrophobic, aggregation-prone regions, thereby accelerating the aggregation kinetics of α-synuclein into misfolded, pathologic forms. C-terminally truncated forms of α-synuclein are abundant in human diseased brains compared to controls, suggesting a role in disease pathogenesis. Factors that alter the homeostatic proteolytic processing of α-synuclein may ultimately tip the balance towards a progressive disease state. Apolipoprotein E (APOE) has been implicated in the acceleration of cognitive impairment in patients with Lewy body diseases. The APOE4 isoform has been found to cause dysregulation in the endosomal–lysosomal pathway, which could result in altered α-synuclein degradation as a potential mechanism for promoting its pathologic misfolding. Herein, we investigate the spatiotemporal accumulation of C-terminally truncated α-synuclein in a seeded and progressive mouse model of synucleinopathy. Furthermore, we study how this process is influenced in the context of mice that are altered to express either the human APOE3 or APOE4 isoforms. We found that specific C-terminal truncation of α-synuclein occurs at early stages of pathogenesis. We also found that proteolytic processing of this domain differs across various brain regions and is influenced by the presence of different human APOE isoforms. Our data demonstrate an early pathogenic role for C-terminally truncated α-synuclein, and highlight the influence of APOE isoforms in modulating its impact.

Introduction

Parkinson’s disease (PD) is a devastating neurodegenerative disorder, characterized by the slow, progressive loss of motor movement function and control due to degeneration, and eventual death, of dopaminergic neurons in the substantia nigra pars compacta [35]. Molecular investigations into the pathophysiology of PD has revealed the misfolding, aggregation and progressive accumulation of α-synuclein (αSyn) as inclusion pathology, termed Lewy bodies (LBs), to be a major recurrent feature in this disease [5]. Furthermore, this protein has been found to accumulate in many other neurodegenerative diseases, termed synucleinopathies [16]. Common symptoms of synucleinopathies include progressive motor dysfunction, however, cognitive features can be a major component, especially for dementia with Lewy bodies [31, 36]. Recent investigations into synucleinopathies with cognitive features have uncovered curious connections to a major Alzheimer’s disease (AD)—associated gene, apolipoprotein E (APOE; HGNC:613). Genome-wide association studies (GWAS) and meta-analyses have exposed the ε4 allele variant of the APOE gene (APOE ε4) as a contributing risk factor for increased rate of cognitive decline, worsened cognitive impairment and/or earlier onset of dementia in synucleinopathies with cognitive features [4, 9, 18, 21, 30, 34, 37,38,39, 41, 48, 49]. Studies on the role of APOE genotype and cognition in PD provide evidence that APOE may directly impact the pathological progression of αSyn in PD [9, 11, 22, 48, 49]; subsequently, in vivo investigations have demonstrated an APOE ε4 mediated exacerbation of αSyn pathology in murine models of synucleinopathy [9, 52]. Furthermore, protein levels of APOE dramatically increase in humans with PD [51], as well as in diseased, transgenic αSyn models with PD-related mutations [14]. These findings confirm a modulatory role for APOE in the pathogenesis of αSyn, however, the molecular mechanisms underlying these observations are not well understood.

One possible mechanism by which APOE influences αSyn pathogenesis is via the dysregulation of autophagic processes in an isoform-dependent manner. Aberrant proteolysis is a major feature in synucleinopathies and is linked to increased αSyn accumulation [3, 6, 12, 15, 27, 32]. αSyn proteolysis leads to the formation of cytotoxic, partially degraded, αSyn fragments [17], and, importantly, carboxy-terminally truncated forms of αSyn (αSynΔC), which are hypothesized to be a key precipitating component of αSyn pathogenesis [2, 25, 28, 44]. In the studies herein, we explored the supposition that αSynΔC contributes to αSyn pathogenesis, as well as the effect of APOE genotype on this process. Using antibodies specific for αSynΔC-103, -114, -122, -125 and -129, which we have recently established, we assessed the extent to which intramuscular (IM), peripheral seeding with αSyn pre-formed fibrils (PFFs) injection into M83 αSyn transgenic animals resulted in the temporal and spatial pathological formation and distribution of αSynΔC species. Furthermore, using M83 transgenic animals altered on either a human APOE ε3+/+ or and human APOE ε4+/+ background, we investigated the effect of APOE genotype on modulating the accumulation of these proteolytically cleaved species.

Materials and methods

Animal research ethics statement

All animal experimental procedures were performed in accordance to University of Florida Institutional Animal Care and Use Committee regulatory policies following approval.

Mouse lines and tissue sources

This study utilized a combination of archival tissues from a previous time course study of Tg(Prnp-SNCA*A53T)+/−, abbreviated hereinafter as TgM83+/− [45], as well as newly generated animals. For the time course study, tissues from a total of 38 TgM83+/− animals were included in this study, 33 of which had been injected intramuscularly with mouse αSyn preformed fibrils (PFFs) and 5 were naïve animals (Summarized in Table 1).

Table 1 Summary of animals used in time-course study
Full size table

M83 mice that co-express humanized APOE alleles were newly generated for this study. APOE targeted replacement mice with either the homozygous APOE ε3 or APOE ε4 humanized alleles [23, 46, 47] were obtained from Dr. Patrick Sullivan (Duke University, Durham, NC). TgM83+/+ mice were crossed with APOE ε3+/+ or APOE ε4+/+ mice to produce the F1 generation; 100% of the offspring were heterozygous for the humanized APOE and TgM83 alleles. Pups from the F1 generation were then backcrossed with the respective homozygous humanized APOE mice, and screened for mice that are homozygous for the APOE ε3 or APOE ε4 alleles and positive for the TgM83 allele resulting in APOE ε3+/+/M83+/− or APOE ε4+/+/M83+/− mice. Mice were mated with respective APOE ε3+/+ or APOE ε4+/+ while screening for the TgM83 allele for two additional generation to be used for the studies. Since humanized APOE ε3+/+ and APOE ε4+/+ mice are on a C57BL/6J background, for comparison, TgM83+/+ mice were mated with non-transgenic (nTg) C57BL/6J mice (Jackson Laboratory) to generate TgM83+/− that were subsequently maintained in a C57BL/6 J for 3–4 generations. Mice were housed in a stable environment with a 12-h light/dark cycle and access to food and water ad libitum. 51 mice were used in total including: 8 TgM83+/− mice, all of which were injected with pre-formed fibrils (PFFs) (6F:2M), 24 APOE ε3+/+/M83+/− mice, 12 (6F:6M) injected with phosphate buffered saline (PBS), 12 (6F:6M) injected with PFFs, and 19 APOE ε4+/+/M83+/− mice, 7 (3F:4M) injected with PBS, 12 (6F:6M) injected with PFFs. Mouse data is summarized in Table 2.

Table 2 Summary of animals used in APOE genotype study
Full size table

αSyn fibril preparation

For the TgM83+/− study with varying APOE isoforms, human PFFs generation was prepared as follows: recombinant human αSyn was expressed in E. coli then purified using size exclusion and ion exchange chromatography as previously described [42]. Human αSyn protein (5 mg/ml in sterile phosphate buffered saline (PBS)) was incubated at 37 °C with constant shaking at 1050 RPM (Thermomixer R, Eppendorf) for 5 days to induce fibrillization. Fibril formation was monitored by K114 [(trans, trans)-1-bromo-2,5-bis-(4-hydroxy) styrylbenzene] fluorometry as previously described [7]. Fibrils were diluted to 2 mg/ml in sterile PBS and fragmented via water bath sonication at 40 kHz for 1 h at RT, prior to injection, as previously described [43].

Gastrocnemius injection and survival analysis

For the time-course study, intramuscular (IM) injection and tissue processing for animals were previously described [45]. Briefly, at 2 months of age, mice were deeply anesthetized with isoflurane (1–5%) inhalation, then bilaterally injected in the gastrocnemius muscles, with 10 µg of mouse αSyn PFFs in 5 µl of sterile PBS. For the APOE/M83+/− study, mice were aged for 2 months, then injected in the right gastrocnemius with 5 µg of human PFFs (1 µg/µl) or sterile PBS. Following inoculation, mice were regularly assessed for motor deficits. For both studies, the survival end point was motor impairment/paralysis, upon which the animals were euthanized. For the APOE/M83+/− study, mice were aged until the onset of motor symptoms or until the pre-determined study end point at 185 days post-injection.

Development and validation of antibodies specific various forms of αSynΔC

Monoclonal antibodies specific for αSyn carboxy (C)-terminally truncated at residues 103, 114, 122, 125 or 129 [20, 40] (see Table 3) were previously described.

Table 3 Summary of antibodies and antigen retrieval methods used in study
Full size table

Tissue processing and immunohistochemical analysis

For immunohistochemistry (IHC) studies, mice were euthanized with CO2, and perfused with a heparin/PBS solution, as previously described [45]. Briefly, brains and spinal cords of mice were harvested and fixed in 70% EtOH/150 mM NaCl, paraffin embedded, and coronally cut into 5 µm sections, as previously described [45]. Immunostaining was performed using established methods [13]. Briefly, tissue sections were rehydrated with xylenes and graded, 100–70% ethanol steps followed with heat-induced epitope retrieval (HIER) in a steam bath for 60 min using retrieval method indicated in Table 3. After antigen retrieval, sections were washed in running deionized H2O for 15 min. For 3H19 antibody and all of the αSyn C-truncation specific antibodies, sections were then treated with 70% formic acid for 10 min, then rinsed in running deionized H2O for 15 min. Endogenous peroxidase was quenched by incubating sections in 1.5% hydrogen peroxide/0.005% Triton-X-100 diluted in PBS, pH 7.4 (Invitrogen) for 15–20 min. For antibody 2G5, Triton-X-100 was omitted from this step. Sections were then rinsed in running deionized H2O for 15 min. Slides were washed 3 times for 5 min in 0.1 M Tris, pH 7.6, or Tris buffered saline (TBS; 50 mM Tris, pH 7.5, 150 mM NaCl) (for 1A2 only), then blocked for 10 min in 2% fetal bovine serum (FBS)/0.1 M Tris solution or 5%milk/TBS (1A2 only). Sections were incubated with primary antibodies diluted in blocking solution, if required, and stored overnight in 4°. After overnight incubation, primary antibody was removed from slides with a quick rinse, then incubated with agitation for 5 min in 0.1M Tris or TBS (for 1A2 only), 3 times. Tissue sections were incubated for 1 h with biotinylated secondary IgG (Vector Laboratories; Burlingame, CA) in 0.1M Tris, pH 7.6/2% FBS or 5%milk/TBS (for 1A2 only) at 1:3000 at RT. For 3H19 antibody and all of the αSyn C-truncation specific antibodies, ImmPRESS polymer secondary antibody (Vector Laboratories; Burlingame, CA) was diluted in a 1:10 ratio with the standard secondary antibody solution described above. Secondary antibody was rinsed 3 times with 0.1M Tris, or TBS (for 1A2 only), for 5 min each. Sections were then incubated with an avidin–biotin complex (ABC) solution (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA) for 1 h at RT, then rinsed again, 3 times, with 0.1M Tris, or TBS (for 1A2 only), for 5 min each. Sections were developed using chromogen 3,3′-diaminobenzidine (DAB kit; KPL, Gaithersburg, MD), rinsed for 15 min in running tap water, then counterstained using hematoxylin (Sigma Aldrich, St. Louis, MO). Summary of antibodies used and corresponding retrieval methods are summarized in Table 3.

Semi-quantification and digital analysis of pathology

All IHC sections were digitally scanned using an Aperio ScanScope CS instrument (40 × magnification; Aperio Technologies Inc., Vista, CA, USA), and images of representative areas of pathology were captured using the ImageScope software (40 × magnification; Aperio Technologies Inc. Vista, CA, USA). Tissue sections were manually scored for αSyn pathology on a scale of 0 (no pathology) to 3 (highest pathology) by three independent raters using the Allen Brain Atlas to define regions (Allen Reference Atlas—Mouse Brain [brain atlas]. Available from atlas.brain-map.org) [1, 8, 19, 26, 33]. Morphological descriptions were classified using categories defined previously [29]. Representative images were corrected for color/hue values; brightness/contrast adjustments were applied identically on captured images within each figure using Adobe Photoshop CS3 (Adobe Systems, San Jose, CA, USA). All raw files are available upon request.

Statistical analysis

Experiments were analyzed using parametric statistical tests described in detail in the figure legends. No animals were excluded from analysis. Data was tested for normality using D’Agostino-Pearson omnibus test. Statistical analysis was performed using Prism software (GraphPad Software, San Diego, CA, USA) and detailed in figure legends. For time-course experiments, results were analyzed using 2-way ANOVA and corrected for multiple comparisons using the Tukey test. Kaplan–Meier curves of motor phenotype development were compared using Log-rank (Mantel–Cox). Column analysis of data with more than 2 groups were analyzed by 1-way ANOVA corrected for multiple comparisons using Tukey’s test. For 2-way ANOVAs, simple effects comparing the mean between groups was reported (detailed in figures). Graphs depicting correlations were computed using Pearson’s correlation coefficients (Pearson r and two-tailed p-value annotated on graphs) and shown with a simple linear regression line with 95% confidence bands of the best-fit line. P values were multiplicity adjusted, family-wise significance was set at 0.05 and data are presented as mean +/− SEM.

Results

Immunohistopathological analysis of PFF intramuscularly injected TgM83+/− mice using novel αSynΔC specific antibodies

To assess the spatiotemporal progression of αSynΔC pathology, we analyzed archival tissues from a cohort of animals that have previously published [45]. In that study, TgM83+/− mice were injected bilaterally in the gastrocnemius muscle with mouse PFFs, or PBS at 2 months of age. PFF-injected mice were harvested at 1-, 2-, or 3- months post injection (m.p.i.), or upon paralysis; naïve mice control mice were harvested at the same timepoints (Fig. 1a).

Fig. 1
figure 1

Schematics of experimental designs assessing the spatiotemporal progression of αSyn inclusion pathology including various αSynΔC forms. (a) Representative illustration of experimental design showing IM injection of PFFs and theorized route of spatiotemporal pathological propagation of αSyn type prion transmission. (b) Stick diagrams of peptide sequences used to generate αSynΔC specific αSyn antibodies. Antibodies are not drawn to scale. Structural model is based on PDB accession 1XQ8. Created with Biorender.com

Full size image

We previously reported that spinal motor neuron degeneration in TgM83+/− mice, begins at approximately 2 months post-IM injection even though pSer129 positive αSyn pathology is limited [45]. We also found that pSer129 positivity increased over time and throughout neuroanatomically connected regions, in PFF-injected mice, while naïve mice display no αSyn pathology [45]. In this study, IHC analysis was performed with αSynΔC specific antibodies, generated and characterized previously, [20, 40] targeting αSynΔC truncated at residues 103, 114, 122, 125, and 129 (Fig. 1b). We investigated whether αSynΔC positivity is detected in regions distal to injection site, and whether burden of αSynΔC positive inclusions increase with age. Similar to staining for pSer129, αSynΔC positivity was not detected in naïve mice [45] (data not shown).

αSynΔC forms of αSyn are detected in the spinal cord at 2-months post IM injection of PFFs and increase temporally

Following IM injection of PFFs in TgM83+/− mice, αSyn inclusion pathology was not detected at 1 m.p.i. as it is first detected at 2 m.p.i. in the intermediate and ventral regions of the spinal cord (Fig. 2) [45]. Therefore, to investigate the earliest occurrence of αSynΔC pathology, we probed spinal tissue with antibodies targeting pSer129 and αSynΔC-103, -114, -122, -125 and -129. Three different C-terminally truncated forms of αSyn, αSynΔC-103 (2G5), αSynΔC-122 (10A4), and αSynΔC-125 (5C1), were detectable in inclusions by 2 m.p.i. (Fig. 2). 2G5 (αSynΔC-103) positive inclusions were found in the anterior horn and intermediate region (Additional file 1: Fig. S1), predominantly as smaller, perinuclear aggregates in glial cells and punctate processes in the neuropil (Fig. 2a). 10A4 (αSynΔC-122) positive inclusions were found in the anterior horn, 5C1 (αSynΔC-125) positive inclusions were found in the lateral anterior horn and intermediate region, and 81A (pSer129) positive inclusions were detected in the anterior and intermediate regions (Additional file 1: Fig. S1) (Fig. 2a). 10A4, 5C1 and 81A positive inclusions shared morphological characteristics, appearing as neuritic processes within the neuropil. By 3 m.p.i., all αSynΔC-specific antibodies detected positive inclusions in the spine, and by terminal endpoint, positive αSyn pathology was detected in both dorsal and ventral regions by all antibodies (Additional file 1: Fig. S1), and these inclusions were larger in size (Fig. 2a). Temporal analysis of 81A and 5C1 positive pathology revealed a linear increase between 2 m.p.i. and terminal endpoint (Fig. 2b). Comparatively, 2G5 pathology was relatively low at 2 m.p.i., but increased greatly in abundance by 3 m.p.i. (Fig. 2b). 1A2 and 2G7 reactive pathology was moderate at 3 m.p.i. and approximately doubled between 3 m.p.i. and end stage (Fig. 2b). 10A4 pathology was moderate at 2 m.p.i., displayed a modest increase at 3 m.p.i., and nearly doubled by terminal endpoint (Fig. 2b). Overall, by terminal endpoint, 2G7 (x-129) immunoreactivity revealed the lowest burden of inclusions, while 2G5 (x-103) staining had the highest (Fig. 2b).

Fig. 2
figure 2

Progressive accumulation of αSyn pathology and αSynΔC forms in the spine of TgM83+/− mice following peripheral intramuscular administration of PFFs. (a) Representative IHC images comparing αSyn pathological deposition in TgM83+/− mice at 1-, 2-, or 3- months post IM injection or terminal stage. Antibodies specific for αSyn phosphorylated at Ser129 (81A) and αSynΔC at residues 103 (2G5), 114 (1A2), 122 (10A4), 125 (5C1) and 129 (2G7) were used for IHC, as indicated. Sections were counterstained with hematoxylin. Scale bar for high magnification images = 150 μm; for inset = 15 μm. (b) Semi-quantification of antibody immunoreactivity for αSyn inclusion pathology. Data expressed as mean +/− SEM. Results were analyzed using 2-way ANOVA and corrected for multiple comparisons using Tukey’s test. n = 8 (4F:4M); 9 (5F:4M); 8 (4F:4M); 8 (5F:3M). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Full size image

αSynΔC-103 and αSynΔC-125 positive pathology detected at 2 m.p.i. in hindbrain

In order to determine whether the temporal pattern of αSynΔC-positive inclusions continues in regions increasingly distal to the injection site, pathology in the hindbrain regions were assessed. In the medulla, the only form of C-terminally truncated αSyn detected at 2 m.p.i. was αSynΔC-103 with antibody 2G5, however, all of αSyn C-truncation epitopes were detected at 3 m.p.i. (Fig. 3a–b). By the terminal endpoint, 2G5 immunoreactive pathology was extensive and widespread in the medulla, including in the reticular formation and lateral vestibular nuclei (LAV) (Fig. 3a). 2G5 inclusions were of distinct morphology, appearing as perinuclear and intranuclear dots, web-like, and ringed cell body inclusions, lightning, corkscrew, and beaded neurites, axonal spheroids and dot-like neuropil (Fig. 3a). Of note, 2G5 inclusion pathology was rare or not found in the interpolar part of the spinal nucleus of the trigeminal (SPVI), inferior olivary complex (IO), or nucleus prepositus (PRP). By the terminal endpoint, medullary 1A2 immunoreactive pathology was regionally constrained, primarily to the gigantocellular reticular nucleus (GRN), the lateral paragigantocellular reticular nucleus (PGRNI), the ventral medullary reticular nucleus (MDRNv), and the magnocellular reticular nucleus (MARN), and rarely in the LAV. (Fig. 3a). By terminal endpoint, medullary 10A4 positive pathology was restricted to the MDRNv, GRN, MARN, PGRNI, the hypoglossal nucleus (cranial nerve (CN) XII), the magnocellular part of the lateral reticular nucleus (LRNm), oral part of the spinal nucleus of the trigeminal (SPVO), spinal vestibular nucleus (SPIV), intermediate reticular nucleus (IRN) and rarely in the LAV, as distorted nucleus, LB-like, flame-shaped inclusions, beaded and corkscrew neurites, dot-like neuropil and neuropil threads (Fig. 3a). By terminal endpoint, medullary 5C1 positive pathology was typically detected in the IRN, MDRNv, nucleus of the solitary tract (NTS), superior vestibular nucleus (SUV), CN XII, dorsal motor nucleus of the vagus nerve (DMX), LRNm, PRP, medial vestibular nucleus (MV), SPIV, SPVI, GRN, IRN, PGRNI and LAV as ringed, LB-like, flame-shaped inclusions, beaded, swollen and corkscrew neurites, dot-like neuropil, and neuropil threads (Fig. 3a). By terminal endpoint, medullary 2G7 positive pathology was detected in the GRN, PGRNI, IRN, MDRNv, LAV and LRNm, as distorted nucleus, swollen neurites, flame-shaped, LB-like and ringed inclusions (Fig. 3a). The pattern of increase in pathological positivity over time in the medullary region was different from that observed in the spinal cord. While the spinal cord showed a more sigmoidal increase in pathological positivity over time, the medullary region displayed a gradual, steady escalation in all forms of αSyn positive pathology at each time point (Fig. 3b). This suggests that the accumulation of pathological positivity in the medulla is more consistent over time compared to the spinal cord, which shows a more variable pattern of accumulation.

Fig. 3
figure 3

Detection of αSynΔC truncated at residues 103 and 125 in the hindbrain of TgM83+/− mice 2 months after peripheral intramuscular PFF inoculation. Representative IHC images and semiquantitative analysis comparing pathological αSyn deposition in TgM83+/− mice at 1-, 2-, 3- months post IM injection or terminal stage in (a, b) the medulla and (c–e) the pons. Antibodies specific for αSyn phosphorylated at Ser129 (81A) and αSynΔC truncated at residues 103 (2G5), 114 (1A2), 122 (10A4), 125 (5C1) and 129 (2G7) were used for IHC, as indicated. Sections were counterstained with hematoxylin. c Nissl (left) and anatomical annotations (right) of coronal section panels from the Allen reference atlas of the adult mouse brain, pons regions analyzed in study are annotated in salmon. Scale bar = 1 mm for low magnitude image and 30 μm for inset in (a) and 60 μm in (d). Data represents mean +/− SEM. Results were analyzed using 2-way ANOVA and corrected for multiple comparisons using Tukey’s test. n = 8 (4F:4M); 9 (5F:4M); 8 (4F:4M); 8 (5F:3M). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Full size image

To analyze regions within the pons for C-terminally truncated forms of αSyn, we immunostained regions illustrated in the annotated reference in Fig. 3c. Along with pSer129 positive pathology, 2G5 and 5C1 were also detected at 2 m.p.i. (Fig. 3d–e). Similar to the pattern revealed in the medulla, all forms of probed C-terminally truncated αSyn were detected at 3 m.p.i. in the pons (Fig. 3d–e). By the terminal endpoint, pontine 2G5 reactive pathology was widespread and appeared as perinuclear dots, LB-like inclusions, axonal spheroids, neuropil threads and dot-like neuropil (Fig. 3d). By the terminal endpoint, pontine 1A2 pathology was moderate and restricted to the pontine reticular nucleus (PRN). 1A2 positive morphology consisted of flame-shaped, globose, dot-like neuropil, neuropil threads, swollen and corkscrew neurites (Fig. 3d). By the terminal endpoint, pontine 10A4 pathology was moderate and limited to the PRN and the nucleus of the lateral lemniscus (NLL). 10A4 positive morphology consisted of distorted nucleus, LB-like, flame-shaped, ringed, and globose inclusions, dot-like neuropil and neuropil threads (Fig. 3d). By the terminal endpoint, pontine 5C1 pathology was moderate and widespread throughout the pons. 5C1 positive inclusions presented as flame-shaped, swollen and corkscrew neurites, dot-like neuropil and neuropil threads (Fig. 3d). By the terminal endpoint, pontine 2G7 pathology was moderate and restricted to the PRN as distorted nucleus, swollen neurites, flame-shaped, globose and ringed inclusions (Fig. 3d). In this region, the rate of pSer129 positive pathology increased steadily across each timepoint, a trend that was roughly recapitulated by 1A2 (αSynΔC-114), 10A4 (αSynΔC-122) and 2G7 (αSynΔC-129) positive pathology (Fig. 3e). In contrast, 2G5 (αSynΔC-103) and 5C1 (αSynΔC-125) positive pathology revealed a more sigmoidal pattern of accumulation over time, wherein a significant spike in immunostaining occurred between 2 and 3 m.p.i., and no significant change in pathology was detected by end stage (Fig. 3e).

αSynΔC positive inclusions detected in neuroanatomically connected regions distal to injection site by end stage in αSyn mice

To determine whether αSynΔC positive inclusions occurred in more distal anatomically connected regions relation to the site of injection, tissue from the midbrain was probed, indicated in pink in the annotated reference in Fig. 4a, of IM PFF-injected TgM83+/− mice with antibodies targeting pSer129 and αSynΔC-103, -114, -122, -125 and -129. At end stage, all forms of C-terminally truncated αSyn investigated in this study were detected in the midbrain (Fig. 4b–c). Analysis of the midbrain reticular nucleus (MRN), periaqueductal gray (PAG), superior colliculus (SCs) and Edinger Westphal nucleus (EW), regions densely populated with pSer129 positive pathology, revealed dramatic heterogeneity in the type of αSynΔC inclusions detected (Fig. 4b). The MRN was highest in 2G5 pathology and moderate in 1A2, 10A4, 5C1 and 2G7 pathology (Fig. 4b). The PAG was high in 2G5, 10A4, 5C1 and 2G7 pathology, and low in 1A2 pathology (Fig. 4b). The SCs was high in 2G5 pathology, moderate in 1A2 pathology, and low in 10A4, 5C1 and 2G7 pathology (Fig. 4b). The EW nucleus was high in 2G5 pathology and low in 1A2, 10A4, 5C1 and 2G7 pathology (Fig. 4b). Across the measured timepoints, pSer129 pathology in the pons exhibited a pattern of gradational increase that was congruent for αSynΔC-positive pathology (Fig. 4c).

Fig. 4
figure 4

Accumulation of αSynΔC in the midbrain of end stage TgM83+/− mice after peripheral intramuscular PFF induction. (a) Nissl (left) and anatomical annotations (right) of coronal section panels from the Allen reference atlas of the adult mouse brain, midbrain regions analyzed in study are annotated in pink. (b, c) Representative IHC images and semi-quantification of antibody immunoreactivity comparing the pathological αSyn deposition of TgM83+/− mice at end stage. Antibodies specific for αSyn phosphorylated at Ser129 (81A) and αSynΔC truncated at 103 (2G5), 114 (1A2), 122 (10A4), 125 (5C1) and 129 (2G7) were used for IHC, as indicated. Sections were counterstained with hematoxylin. Scale bar = 100 μm. Data expressed as mean +/− SEM. Results were analyzed using 2-way ANOVA and corrected for multiple comparisons using Tukey’s test. n = 8 (4F:4M); 9 (5F:4M); 8 (4F:4M); 8 (5F:3M). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Full size image

Humanized APOE/M83+/− mice develop mature αSyn inclusion pathology after intramuscular inoculation with PFFs

To investigate the effect of human ApoE isoforms on αSynΔC positive pathology, we generated mouse models of synucleinopathy with the background of different human APOE genotypes, by backcrossing the offspring of M83+/+ mice and homozygous humanized APOE ε4 or ε3 mice with M83+/− mice for at least 2 generations to APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice (see Materials and Methods). Since humanized APOE mice are on a BL6 background, M83+/− on a BL6 background were also generated for comparison. At 2 months of age, these mice were unilaterally IM injected with human αSyn PFFs. The mice were aged until the onset of fatal motor symptoms, whereupon the brains and spine were collected for IHC analysis.

To determine the profile of pathologic αSyn in these mice, brains and spinal cords from APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice injected with PFFs were assessed for markers of mature αSyn inclusion pathology using antibodies directed towards pSer129 (81A), as a measure of disease-associated αSyn, αSyn at the N-terminus (2H6) and C-terminus (3H19), as well as sequestrasome1 (p62). M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice showed robust and extensive, widespread αSyn pathology at end stage (Fig. 5a, Additional file 1: Fig. S2). APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice injected with PBS did not develop αSyn pathology (Additional file 1: Fig. S3). Semi-quantification of 81A pathology revealed a significantly lower level of hypothalamic inclusions in APOE ε4+/+/M83+/− mice compared to M83+/− mice (Fig. 5b), however, all other regions were relatively equal. Analysis of the onset of a motor phenotype revealed no difference between PFF-injected M83+/− mice (n = 8; median survival, 123 days after injection), APOE ε3+/+/M83+/− (n = 12; median survival, 112 days after injection), or APOE ε4+/+/M83+/− mice (n = 12; median survival, 115 days after injection) (Fig. 5c).

Fig. 5
figure 5

CNS accumulation of αSyn inclusion pathology in APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice after intramuscular inoculation with PFFs. (a) Representative images of immunostaining with an antibody specific for αSyn phosphorylated at serine 129 (81A). Brains and spinal cord from APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice were assessed for relative pathological burden in M83+/−mice. Scale bar = 100 μm. (b) Semi-quantification of 81A (pSer129) immunoreactivity in the spinal cord, medulla, pons, midbrain, hypothalamus, thalamus, cortex and striatum of PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice were scored by 3 independent observers. Results were analyzed using 1-way ANOVA and corrected for multiple comparisons using Tukey’s test. Data represents means +/− SEM*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (c) Kaplan–Meier analysis of motor phenotype development in PFF-injected M83+/− (n = 8; median survival, 123 days after injection), APOE ε3+/−/M83+/− (n = 12; median survival, 112 days after injection), and APOE ε4+/−/M83+/− mice (n = 12; median survival, 115 days after injection) see Table 2. Overall Log-rank (Mantel–Cox) p = 0.4904

Full size image

Regionally dynamic αSynΔC immunoreactive pathology is differentially regulated by APOE genotype

In order to compare the overall burden of αSynΔC positive inclusions, IHC analysis was performed using antibodies targeted towards αSyn C-terminally truncated at residue 103, 114, 122, 125, and 129. Regions within the spine and brain, ranging in distance to the injection site including the spinal cord, medulla, pons, midbrain, hypothalamus, thalamus, cortex and striatum were analyzed. Immunostained sections were evaluated via semi-quantitative analysis by 3 independent observers and averaged score were normalized to 81A (Fig. 6). The data for all the αSynΔC antibodies, regions analyzed and genotypes are shown in Fig. 6 for easier direct comparison. Our data revealed that αSynΔC immunoreactivity was regionally dynamic, and that this was altered based on APOE genotype. This was analyzed in greater detail for each αSynΔC antibody. αSynΔC-103 (2G5) immunoreactivity was higher in the spine, hindbrain and midbrain for all cohorts compared to forebrain regions (Fig. 7a). For regions that displayed genotype-specific differences such as the spinal cord, pons and cortex, we performed additional statistical analyses (Fig. 7b–c). In the spine, both APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice exhibited significantly higher levels of 2G5 pathology compared to M83+/− mice, however, αSynΔC-103 pathology in this region failed to show a significant correlation to days to terminal motor symptoms (Fig. 7b). In the pons, αSynΔC-103 immunoreactivity was higher in M83+/− than in APOE ε4+/+/M83+/− mice (Fig. 7c), while, cortical αSynΔC-103 positive pathology was highest in APOE ε4+/+/M83+/− mice (Fig. 7d). Interestingly, αSynΔC-103 immunoreactivity in the pons and cortex was associated with elongated survival in M83+/−, but not in APOE ε3+/+/M83+/− or APOE ε4+/+/M83+/− (Fig. 7c–d).

Fig. 6
figure 6

Regionally dynamic αSynΔC immunoreactive pathology is differentially regulated by APOE genotype. The burden of αSynΔC positive inclusions in the spinal cord, medulla, pons, midbrain, hypothalamus, thalamus, cortex and striatum of PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice were scored by 3 independent observers. Averaged scores were normalized to 81A (pSer129) and analyzed using 2-way ANOVA and corrected using Tukey’s multiple comparisons test. Data represents means +/− SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Full size image
Fig. 7
figure 7

αSynΔC-103 immunoreactivity in the pons and cortex is associated with survival in time in M83+/− intramuscular injected with PFFs, but not in APOE ε4+/+/M83+/− or APOE ε3+/+/M83+/−. (a) Graph summarizing burden of αSynΔC-103 positive inclusions in the spinal cord (SC), medulla (MY), pons, midbrain (MB), hypothalamus (HY), thalamus (TH), cortex (CTX) and striatum (STR) of PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice depicted as mean with SEM. (b) Semi-quantification and representative images of αSynΔC-103 immunoreactivity with correlational analysis between spinal αSynΔC-103 immunoreactivity and d.p.i. for each cohort. (c) Semi-quantification and representative images of αSynΔC-103 immunoreactivity with correlational analysis between αSynΔC-103 immunoreactivity in the pons and d.p.i. for each cohort. (d) Semi-quantification and representative images of αSynΔC-103 immunoreactivity with correlational analysis between αSynΔC-103 immunoreactivity in the cortex and d.p.i. for each cohort. Results were analyzed using 2-way ANOVA and corrected using Tukey’s multiple comparisons test; data represent means +/− SEM. Pearson correlation coefficients between αSynΔC positivity and d.p.i. were computed with the assumption that data are sampled from Gaussian distribution. Pearson r and two-tailed p-values are indicated on graph. Simple linear regression is shown with dotted lines depicting 95% confidence intervals. n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bar = 100 μm

Full size image

Evaluation of αSynΔC-114 (1A2) immunostaining revealed moderate positivity in the spine, hindbrain and midbrain and relative few positive inclusions within the forebrain for all cohorts (Fig. 8a). For regions that displayed genotype-specific differences such as the medulla and midbrain, we performed additional statistical analyses (Fig. 8b, c). APOE ε3+/+/M83+/− mice had greater 1A2-positive inclusion pathology in the medulla compared to M83+/− (Fig. 8b) and in the midbrain compared to APOE ε4+/+/M83+/− mice (Fig. 8c). αSynΔC-114 immunoreactivity in the medulla but not in the midbrain was positively associated with days to terminal motor symptoms in APOE ε4+/+/M83+/− mice (Fig. 8b, c). There was no association between 1A2-positive inclusion pathology and days to terminal motor symptoms post PFF injection for the other genotypes.

Fig. 8
figure 8

Medullary αSynΔC-114 inclusion pathology is positively correlated with onset of motor symptoms in APOE ε4+/+/M83+/− mice. (a) Graph summarizing burden of αSynΔC-114 positive inclusions in the spinal cord (SC), medulla (MY), pons, midbrain (MB), hypothalamus (HY), thalamus (TH), cortex (CTX) and striatum (STR) of PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice depicted as mean with SEM. (b) Semi-quantification and representative images of αSynΔC-114 immunoreactivity in the medulla with correlational analysis between αSynΔC-114 immunoreactivity and d.p.i. for each cohort. (c) Semi-quantification and representative images of αSynΔC-114 immunoreactivity with correlational analysis between αSynΔC-114 immunoreactivity in the midbrain and d.p.i. for each cohort. M83+/− horizontal line. Results were analyzed using 2-way ANOVA and corrected using Tukey’s multiple comparisons test; data represent means +/− SEM. Pearson correlation coefficients between αSynΔC positivity and d.p.i. were computed with the assumption that data are sampled from Gaussian distribution. Pearson r and two-tailed p-values are indicated on graph. Simple linear regression is shown with dotted lines depicting 95% confidence intervals. n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bar = 100 μm

Full size image

Examination of αSynΔC-122 (10A4) immunostaining revealed a higher burden of positive pathology in the spine, hindbrain and midbrain for all cohorts compared to forebrain regions (Fig. 9a). For regions that displayed genotype-specific differences, such as the spinal cord, midbrain, hypothalamus and thalamus, we performed additional statistical analyses (Fig. 9b–e). M83+/− mice demonstrated a greater burden of 10A4 positive inclusion pathology compared to APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice in the spine (Fig. 9b). In the midbrain and hypothalamus, M83+/− and APOE ε4+/+/M83+/− mice both exhibited greater levels of αSynΔC-122 (10A4) positive immunostaining compared to APOE ε3+/+/M83+/− mice (Fig. 9c–d). However, in the thalamus, M83+/− mice again demonstrated a greater burden of 10A4 positive inclusion pathology in comparison to APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice (Fig. 9e). Interestingly, thalamic 10A4 positivity in APOE ε4+/+/M83+/− mice positively correlated with a later onset of motor symptoms.

Fig. 9
figure 9

αSynΔC-122 immunoreactivity is constrained to the spine and brainstem and is significantly lower in APOE ε3+/+/M83+/− mice compared to M83+/−. (a) Graph summarizing burden of αSynΔC-122 positive inclusions in the spinal cord (SC), medulla (MY), pons, midbrain (MB), hypothalamus (HY), thalamus (TH), cortex (CTX) and striatum (STR) of PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice depicted as mean with SEM. (b) Semi-quantification and representative images of αSynΔC-122 immunoreactivity with correlational analysis between spinal αSynΔC-122 immunoreactivity and d.p.i. for each cohort. (c) Semi-quantification and representative images of αSynΔC-122 immunoreactivity with correlational analysis between αSynΔC-122 immunoreactivity in the midbrain and d.p.i. for each cohort. (d) Semi-quantification and representative images of αSynΔC-122 immunoreactivity with correlational analysis between αSynΔC-122 immunoreactivity in the hypothalamus and d.p.i. for each cohort. (e) Semi-quantification and representative images of αSynΔC-122 immunoreactivity with correlational analysis between αSynΔC-122 immunoreactivity in the thalamus and d.p.i. for each cohort. Results were analyzed using 2-way ANOVA and corrected using Tukey’s multiple comparisons test; data represent means +/− SEM. Pearson correlation coefficients between αSynΔC positivity and d.p.i. were computed with the assumption that data are sampled from Gaussian distribution. Pearson r and two-tailed p-values are indicated on graph. Simple linear regression is shown with dotted lines depicting 95% confidence intervals. n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bar = 100 μm

Full size image

Analysis of αSynΔC-125 (5C1) immunostaining revealed a decreasing trend of positive pathology in all cohorts, as distance from injection site increased (Fig. 10a). Further analysis revealed that APOE ε4+/+/M83+/− mice exhibited greater pontine 5C1-positive pathology compared to M83+/− mice, however, there was no correlation with onset of terminal motor symptoms post PFF injection (Fig. 10b).αSynΔC-129 (2G7) immunostaining of αSyn pathological inclusions was also more abundant closer to the injection site, including the spine, hindbrain and midbrain compared to forebrain regions (Fig. 6) but there was no statistically significant difference between any of the genotypes injected with PFFs.

Fig. 10
figure 10

APOE ε4+/+/M83+/− mice develop a greater burden of αSynΔC-125 positive pontine pathology compared to M83+/−mice. (a) Graph summarizing burden of αSynΔC-125 positive inclusions in the spinal cord (SC), medulla (MY), pons, midbrain (MB), hypothalamus (HY), thalamus (TH), cortex (CTX) and striatum (STR) of intramuscular PFF-injected M83+/−, APOE ε4+/+/M83+/− and APOE ε3+/+/M83+/− mice depicted as mean with SEM. (b) Semi-quantification and representative images of αSynΔC-125 immunoreactivity with correlational analysis between αSynΔC-125 immunoreactivity in the pons and d.p.i. for each cohort. Results were analyzed using 2-way ANOVA and corrected using Tukey’s multiple comparisons test; data represent means  +/-SEM. Pearson correlation coefficients between αSynΔC positivity and d.p.i. were computed with the assumption that data are sampled from Gaussian distribution. Pearson r and two-tailed p-values are indicated on graph. Simple linear regression is shown with dotted lines depicting 95% confidence intervals. n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bar = 100 μm

Full size image

Discussion

Our study investigated the spatiotemporal characterization of a series of αSynΔC species that occurs during pathogenesis in a peripheral to CNS seeded model of synucleinopathies. This IM seeding model provides the ability to assess changes associated with the processive spatial formation of αSyn pathology along predicted neuroanatomical pathways following the prion-type neuroinvasion of the CNS. Our findings revealed concurrent accumulation of αSynΔC with αSyn phosphorylated at pSer129, as well as an APOE isoform-dependent alteration of αSynΔC-positive inclusion accumulation (Fig. 11), suggesting that proteolytic processing of αSyn may be a key component to the early stages of pathology and may differentiate stages of disease progression. Our findings show that αSynΔC-103, -122 and -125 occur at detectable levels in αSyn aggregrates as early as 2 m.p.i. when the formation of αSyn pathology starts, and that by the terminal endpoint, αSynΔC-103, -114, -122, -125 and -129 are all observed, at various levels, in pathological inclusions in synaptically connected regions, throughout the neuroaxis (Fig. 11a). Furthermore, we demonstrate that while αSyn-APOE mice develop mature αSyn inclusion pathology and paralysis, at a rate not significantly different from TgM83+/− controls, the regionality and disposition of αSynΔC positive pathology is indeed influenced by the presence of different APOE alleles (Fig. 11b), although the mechanism is unclear. This suggests a role for ApoE isoforms in the regulation of αSyn metabolism; further studies are needed to elaborate upon this relationship.

Fig. 11
figure 11

Schematic summary of the observed pathological findings in various CNS regions, using C-terminally truncated αSyn-specific antibodies. Diagram illustrating data from the (a) time-course study and (b) the APOE study, depicting the relative levels of detected C-terminally truncated αSyn across the neuroaxis. Created with Biorender.com

Full size image

In this study, we characterized the temporal and spatial accumulation of carboxy-truncated αSyn at specific residues (103, 114, 122, 125, and 129) in the CNS after PFF injection into the hindleg gastrocnemius muscle of different TgM83 +/− based mouse models. Intramuscular PFF injection is a useful tool for modeling the prion-like spread of seeds through connected neuron populations, as this method of neuroinvasion follows defined groups of neurons in the spinal cord, thereby not confounded by possible dissemination that may occur with intracerebral injections. For spatiotemporal analysis in our time-course study, we analyzed the mice at 1-, 2-, and 3- months post injection, as well as at terminal stage (approximately 4 months), in regions increasingly distal from injection site. Previously, we have shown the temporal progression of αSyn inclusion pathology in the CNS after hindleg IM injection of PFFs in TgM83+/− mice, with subsequent astroglial and microglial activation [45]. We demonstrated that peripheral PFF injection induced pSer129 + αSyn inclusion pathology in the spine and midbrain by 2 m.p.i., and the ventral thalamus and cortex by 3 m.p.i. Our findings have revealed that some forms of αSynΔC appear at timepoints concurrent with the onset of pSer129 accumulation, while others are not detected until later timepoints (Fig. 11). We have also shown that αSynΔC species progressively accumulate, predominantly in neuroanatomically connected regions, and, by end stage, many reach regions distal from the injection site (Fig. 11). Possible molecular explanations for this include a prion-like mechanism of intercellular spread that is recapitulated in the templated accumulation of αSynΔC, wherein truncated species are recruited into fibril assembly. In this model, proteolytic processing of αSyn occurs prior to fibril formation, meaning that aggregate elongation would be dictated by enzymatic activity. Alternatively, proteolytic degradation of αSyn may occur after fibril formation, where aggregated, full length αSyn proteins are partially degraded by proteases, which remove segments from the C-terminus, exposing the epitopes detected by αSynΔC-specific antibodies.

Interestingly, C-truncated αSyn pathology presentation skyrockets in the spine by 3 m.p.i., especially αSyn truncated at residue 103, which is also when we first detected elevated levels of GFAP, cd11b, and Iba1 positivity [45]. These findings suggest that the accumulation of specific αSyn carboxy-truncated species, particularly αSynΔC-103, may play a critical role in the rapid stages of prion-like spread of αSyn pathology.  Furthermore, the temporal and spatial accumulation patterns of αSynΔC-103 positive inclusions differ from those of other αSynΔC positive inclusions examined in this study, suggesting that proteolysis of αSyn may occur in a specific and regulated manner during the progression of synucleinopathies. Moreover, the fact that the increase in detection of C-terminally truncated αSyn is temporally associated with the occurrence of neuroinflammation indicates that proteolysis may be a contributing factor to the pathogenesis of synucleinopathies by promoting a pro-inflammatory environment. These insights may have important implications for understanding the molecular mechanisms underlying synucleinopathies and developing targeted therapies aimed at preventing or slowing their progression. Future studies will investigate the role of the individual αSynΔC species in modulating the initiation and progression of prion-type αSyn pathogenesis and the impact on associated neuroinflammation.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

References

  1. Allen Institute for Brain Science (2004) Interactive Atlas viewer: Atlas viewer. In: Allen mouse brain atlas. Accessed 13 Mar 2023

  2. Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG (2016) Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 113:9593–9598. https://doi.org/10.1073/pnas.1609291113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Behl T, Kumar S, Althafar ZM, Sehgal A, Singh S, Sharma N, Badavath VN, Yadav S, Bhatia S, Al-Harrasi A, Almoshari Y, Almikhlafi MA, Bungau S (2022) Exploring the role of ubiquitin-proteasome system in Parkinson’s disease. Mol Neurobiol 59:4257–4273. https://doi.org/10.1007/s12035-022-02851-1

    Article  CAS  PubMed  Google Scholar 

  4. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, Halliday GM, Mann D, Pickering-Brown S, Dickson DW, Singleton A, Hardy J (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 23:6139–6146. https://doi.org/10.1093/hmg/ddu334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Burré J, Sharma M, Südhof TC (2018) Cell biology and pathophysiology of α-synuclein. Cold Spring Harb Perspect Med 8:a024091. https://doi.org/10.1101/cshperspect.a024091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chen L, Thiruchelvam MJ, Madura K, Richfield EK (2006) Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol Dis 23:120–126. https://doi.org/10.1016/j.nbd.2006.02.004

    Article  CAS  PubMed  Google Scholar 

  7. Crystal AS, Giasson BI, Crowe A, Kung MP, Zhuang ZP, Trojanowski JQ, Lee VMY (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J Neurochem 86:1359–1368. https://doi.org/10.1046/j.1471-4159.2003.01949.x

    Article  CAS  PubMed  Google Scholar 

  8. Daigle TL, Madisen L, Hage TA, Valley MT, Knoblich U, Larsen RS, Takeno MM, Huang L, Gu H, Larsen R, Mills M, Bosma-Moody A, Siverts LA, Walker M, Graybuck LT, Yao Z, Fong O, Nguyen TN, Garren E, Lenz GH, Chavarha M, Pendergraft J, Harrington J, Hirokawa KE, Harris JA, Nicovich PR, McGraw MJ, Ollerenshaw DR, Smith KA, Baker CA, Ting JT, Sunkin SM, Lecoq J, Lin MZ, Boyden ES, Murphy GJ, da Costa NM, Waters J, Li L, Tasic B, Zeng H (2018) A suite of transgenic driver and reporter mouse lines with enhanced brain-cell-type targeting and functionality. Cell 174:465-480.e22. https://doi.org/10.1016/j.cell.2018.06.035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM (2020) APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med 12:eaay3069. https://doi.org/10.1126/scitranslmed.aay3069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dhillon J-KS, Riffe C, Moore BD, Ran Y, Chakrabarty P, Golde TE, Giasson BI (2017) A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS ONE 12:e0184731. https://doi.org/10.1371/journal.pone.0184731

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL, Diehl NN, van Gerpen JA, Uitti RJ, Wszolek ZK, Ertekin-Taner N, Knopman DS, Petersen RC, Graff-Radford NR, Boeve BF, Bu G, Ferman TJ, Ross OA (2018) APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 91:e1182–e1195. https://doi.org/10.1212/WNL.0000000000006212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dikic I (2017) Proteasomal and autophagic degradation systems. Annu Rev Biochem 86:193–224. https://doi.org/10.1146/annurev-biochem-061516-044908

    Article  CAS  PubMed  Google Scholar 

  13. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VMY, Trojanowski JQ (2000) Immunohistochemical and biochemical studies demonstrate a distinct profile of α-Synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 59:830–841. https://doi.org/10.1093/jnen/59.9.830

    Article  CAS  PubMed  Google Scholar 

  14. Gallardo G, Schlüter OM, Südhof TC (2008) A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat Neurosci 11:301–308. https://doi.org/10.1038/nn2058

    Article  CAS  PubMed  Google Scholar 

  15. Giasson BI, Lee VMY (2003) Are ubiquitination pathways central to parkinson’s disease? Cell 114:1–8. https://doi.org/10.1016/S0092-8674(03)00509-9

    Article  CAS  PubMed  Google Scholar 

  16. Goedert M, Jakes R, Spillantini MG (2017) The synucleinopathies: twenty years on. J Parkinsons Dis 7:S51–S69. https://doi.org/10.3233/JPD-179005

    Article  PubMed  PubMed Central  Google Scholar 

  17. Grassi D, Howard S, Zhou M, Diaz-Perez N, Urban NT, Guerrero-Given D, Kamasawa N, Volpicelli-Daley LA, LoGrasso P, Lasmézas CI (2018) Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease. Proc Natl Acad Sci U S A 115:E2634–E2643. https://doi.org/10.1073/pnas.1713849115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday GM, Hardy J, Trojanowski JQ, Dickson DW, Singleton A, Stone DJ, Bras J (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64–74. https://doi.org/10.1016/S1474-4422(17)30400-3

    Article  PubMed  Google Scholar 

  19. Harris JA, Mihalas S, Hirokawa KE, Whitesell JD, Choi H, Bernard A, Bohn P, Caldejon S, Casal L, Cho A, Feiner A, Feng D, Gaudreault N, Gerfen CR, Graddis N, Groblewski PA, Henry AM, Ho A, Howard R, Knox JE, Kuan L, Kuang X, Lecoq J, Lesnar P, Li Y, Luviano J, McConoughey S, Mortrud MT, Naeemi M, Ng L, Oh SW, Ouellette B, Shen E, Sorensen SA, Wakeman W, Wang Q, Wang Y, Williford A, Phillips JW, Jones AR, Koch C, Zeng H (2019) Hierarchical organization of cortical and thalamic connectivity. Nature 575:195–202. https://doi.org/10.1038/s41586-019-1716-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hass EW, Sorrentino ZA, Xia Y, Lloyd GM, Trojanowski JQ, Prokop S, Giasson BI (2021) Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies. Acta Neuropathol Commun 9:146. https://doi.org/10.1186/s40478-021-01242-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Huang X, Chen P, Kaufer DI, Tröster AI, Poole C (2006) Apolipoprotein E and dementia in Parkinson disease: A meta-analysis. Arch Neurol 63:189–193

    Article  PubMed  Google Scholar 

  22. Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, Heckman MG, Ikezu TC, Li Z, Burgess JD, Amerna D, O’Leary J, DeTure MA, Zhao J, McLean PJ, Dickson DW, Ross OA, Bu G, Zhao N (2022) APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer’s disease with Lewy body pathology. Acta Neuropathol 143:641–662. https://doi.org/10.1007/s00401-022-02421-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N (1999) Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 103:1579–1586. https://doi.org/10.1172/JCI6172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α-Synuclein, Ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253. https://doi.org/10.1093/jnen/62.12.1241

    Article  CAS  PubMed  Google Scholar 

  25. Lashuel HA, Mahul-Mellier A-L, Novello S, Hegde RN, Jasiqi Y, Altay MF, Donzelli S, DeGuire SM, Burai R, Magalhães P, Chiki A, Ricci J, Boussouf M, Sadek A, Stoops E, Iseli C, Guex N (2022) Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. npj Park Dis 8:136. https://doi.org/10.1038/s41531-022-00388-7

    Article  CAS  Google Scholar 

  26. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivisay T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu MB, Young RC, Youngstrom BL, Yuan XF, Zhang B, Zwingman TA, Jones AR (2007) Genome-wide atlas of gene expression in the adult mouse brain. Nature 445:168–176. https://doi.org/10.1038/nature05453

    Article  CAS  PubMed  Google Scholar 

  27. Liu B, Ruan J, Chen M, Li Z, Manjengwa G, Schlüter D, Song W, Wang X (2022) Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases. Mol Psychiatry 27:259–268. https://doi.org/10.1038/s41380-021-01233-8

    Article  CAS  PubMed  Google Scholar 

  28. Liu CW, Giasson BI, Lewis KA, Lee VM, DeMartino GN, Thomas PJ (2005) A precipitating role for truncated α-synuclein and the proteasome in α-synuclein aggregation: Implications for pathogenesis of parkinson disease. J Biol Chem 280:22670–22678. https://doi.org/10.1074/jbc.M501508200

    Article  CAS  PubMed  Google Scholar 

  29. Lloyd GM, Sorrentino ZA, Quintin S, Gorion K-MM, Bell BM, Paterno G, Long B, Prokop S, Giasson BI (2022) Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice. Acta Neuropathol 143:663–685. https://doi.org/10.1007/s00401-022-02425-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405–1412. https://doi.org/10.1001/jamaneurol.2014.1455

    Article  PubMed Central  Google Scholar 

  31. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O’Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies. Neurology 89:88–100

    Article  PubMed  PubMed Central  Google Scholar 

  32. Nonaka T, Iwatsubo T, Hasegawa M (2005) Ubiquitination of α-synuclein. Biochemistry 44:361–368. https://doi.org/10.1021/bi0485528

    Article  CAS  PubMed  Google Scholar 

  33. Oh SW, Harris JA, Ng L, Winslow B, Cain N, Mihalas S, Wang Q, Lau C, Kuan L, Henry AM, Mortrud MT, Ouellette B, Nguyen TN, Sorensen SA, Slaughterbeck CR, Wakeman W, Li Y, Feng D, Ho A, Nicholas E, Hirokawa KE, Bohn P, Joines KM, Peng H, Hawrylycz MJ, Phillips JW, Hohmann JG, Wohnoutka P, Gerfen CR, Koch C, Bernard A, Dang C, Jones AR, Zeng H (2014) A mesoscale connectome of the mouse brain. Nature 508:207–214. https://doi.org/10.1038/nature13186

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Okubadejo NU, Okunoye O, Ojo OO, Arabambi B, Akinyemi RO, Osaigbovo GO, Abubakar SA, Iwuozo EU, Wahab KW, Agabi OP, Agulanna U, Imarhiagbe FA, Abiodun OV, Achoru CO, Adebowale AA, Adeniji O, Akpekpe JE, Ali MW, Ani-Osheku I, Arigbodi O, Balarabe SA, Bello AH, Ekenze OS, Erameh CO, Farombi TH, Fawale MB, Komolafe MA, Nwani PO, Nwazor EO, Nyandaiti Y, Obehighe EE, Obiabo YO, Odeniyi OA, Odiase FE, Ojini FI, Onwuegbuzie GA, Osemwegie N, Oshinaike OO, Otubogun FM, Oyakhire SI, Taiwo FT, Williams UE, Ozomma S, Zubair Y, Hernandez D, Bandres-Ciga S, Blauwendraat C, Singleton A, Houlden H, Hardy J, Rizig M (2022) APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson’s disease. npj Park Dis 8:155. https://doi.org/10.1038/s41531-022-00411-x

    Article  CAS  Google Scholar 

  35. Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, Chesselet M-F, Hardy J, Madeo G, McKeith I, Mollenhauer B, Moore DJ, Rascol O, Schlossmacher MG, Soreq H, Stefanis L, Ferreira JJ (2023) Defining the riddle in order to solve it: there is more than one “Parkinson’s disease.” Mov Disord Epub ahead. https://doi.org/10.1002/mds.29419

    Article  Google Scholar 

  36. Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, Attems J, McKeith I (2019) Dementia with Lewy bodies: an update and outlook. Mol Neurodegener 14:5. https://doi.org/10.1186/s13024-019-0306-8

    Article  PubMed  PubMed Central  Google Scholar 

  37. Paul KC, Rausch R, Creek MM, Sinsheimer JS, Bronstein JM, Bordelon Y, Ritz B (2016) APOE, MAPT, and COMT and Parkinson’s disease susceptibility and cognitive symptom progression. J Parkinsons Dis 6:349–359. https://doi.org/10.3233/JPD-150762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Payami H, Nutt J, Kaye J, Bird T, Camicioli R, Zareparsi S, Sexton G, Swanson P (2002) Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 107:156–161. https://doi.org/10.1002/ajmg.10111

    Article  PubMed  Google Scholar 

  39. Pu JL, Jin CY, Wang ZX, Fang Y, Li YL, Xue NJ, Zheng R, Lin ZH, Yan YQ, Si XL, Chen Y, Liu Y, Song Z, Yan YP, Tian J, Yin XZ, Zhang BR (2022) Apolipoprotein E genotype contributes to motor progression in Parkinson’s disease. Mov Disord 37:196–200. https://doi.org/10.1002/mds.28805

    Article  CAS  PubMed  Google Scholar 

  40. Quintin S, Lloyd GM, Paterno G, Xia Y, Sorrentino Z, Bell BM, Gorion K-M, Lee EB, Prokop S, Giasson BI (2023) Cellular processing of α-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J Biol Chem 299:104912. https://doi.org/10.1016/j.jbc.2023.104912

    Article  CAS  PubMed  Google Scholar 

  41. Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA (2019) GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep 9:7013. https://doi.org/10.1038/s41598-019-43458-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI (2014) Intramuscular injection of -synuclein induces CNS -synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci 111:10732–10737. https://doi.org/10.1073/pnas.1321785111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sorrentino ZA, Brooks MMT, Hudson V, Rutherford NJ, Golde TE, Giasson BI, Chakrabarty P (2017) Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol Neurodegener 12:40. https://doi.org/10.1186/s13024-017-0182-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sorrentino ZA, Giasson BI (2020) The emerging role of α-synuclein truncation in aggregation and disease. J Biol Chem 295:10224–10244. https://doi.org/10.1074/jbc.REV120.011743

    Article  CAS  PubMed Central  Google Scholar 

  45. Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C, Sacino AN, Price ND, Golde TE, Giasson BI, Chakrabarty P (2018) Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration. Neurobiol Dis 120:98–106. https://doi.org/10.1016/j.nbd.2018.09.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272:17972–17980. https://doi.org/10.1074/jbc.272.29.17972

    Article  CAS  PubMed  Google Scholar 

  47. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human APOE*2. J Clin Invest 102:130–135. https://doi.org/10.1172/JCI2673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grødem J (2022) GBA and APOE Impact cognitive decline in Parkinson’s disease: a 10-year population-based study. Mov Disord 37:1016–1027. https://doi.org/10.1002/mds.28932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP (2013) APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70:223–228. https://doi.org/10.1001/jamaneurol.2013.600

    Article  PubMed  PubMed Central  Google Scholar 

  50. Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67:402–416. https://doi.org/10.1097/NEN.0b013e31816fc995

    Article  CAS  PubMed  Google Scholar 

  51. Wilhelmus MMM, Bol JGJM, Van Haastert ES, Rozemuller AJM, Bu G, Drukarch B, Hoozemans JJM (2011) Apolipoprotein e and LRP1 increase early in Parkinson’s disease pathogenesis. Am J Pathol 179:2152–2156. https://doi.org/10.1016/j.ajpath.2011.07.021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J, Van Ingelgom AJ, Davis MD, Kurti A, Knight JA, Linares C, Chen Y, Delenclos M, Liu C-C, Fryer JD, Asmann YW, McLean PJ, Dickson DW, Ross OA, Bu G (2020) APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med 12:eaay1809. https://doi.org/10.1126/scitranslmed.aay1809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Institute of Neurological Disorders and Stroke (R01NS089022, R01NS100876, RF1NS129567, RF1AG057933). G.M.L. was supported by T32NS082168 training grant from National Institute of Neurological Disorders and Stroke. Z.A.S. was supported by fellowship F30AG063446 from the National Institute on Aging.

Author information

Authors and Affiliations

  1. Department of Neuroscience, College of Medicine, University of Florida, BMS J483/CTRND, 1275 Center Drive, Gainesville, FL, 32610, USA

    Grace M. Lloyd, Brooke Long, Stephan Quintin, Zachary A. Sorrentino, Kimberly-Marie M. Gorion, Brach M. Bell, Denise Carrillo, David Borchelt & Benoit I. Giasson

  2. Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA

    Grace M. Lloyd, Stephan Quintin, Zachary A. Sorrentino, Kimberly-Marie M. Gorion, Brach M. Bell, David Borchelt & Benoit I. Giasson

  3. McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA

    David Borchelt & Benoit I. Giasson

  4. Department of Medicine, Duke University School of Medicine, Durham, NC, USA

    Patrick Sullivan

Authors
  1. Grace M. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brooke Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan Quintin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zachary A. Sorrentino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kimberly-Marie M. Gorion
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brach M. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Denise Carrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrick Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Borchelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Benoit I. Giasson
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GML, DB, and BIG designed the experiments. GML, BL, ZAS, SQ, BB, KG, DC, and BIG. performed the experiments. PS and DB provided key experimental resources. GML wrote the manuscript. BIG reviewed and edited manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Benoit I. Giasson.

Ethics declarations

Ethics approval and consent to participate

All procedures were performed according to the National Institute of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Florida Institutional Animal Care and Use Committee.

Competing interests

We declare no competing interest in this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

. Figure S1: Low magnification images depicting accumulation of C-terminally truncated αSyn in the spine of TgM83+/− mice following intramuscular administration of PFFs. Representative IHC images comparing the pathological deposition of αSyn TgM83+/− mice at 1-, 2-, 3- months post injection or terminal stage. Antibodies specific for αSyn phosphorylated at Ser129 (81A) and αSyn truncated at residues 103 (2G5), 114 (1A2), 122 (10A4), 125 (5C1) or 129 (2G7) were used for IHC, as indicated. Sections were counterstained with hematoxylin. Scale bar = 300 μm. Figure S2: Representative images of immunostaining with antibodies specific for αSyn (2H6 and 3H19) and p62/sequestrasome-1. Brains and spinal cord from APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice at end stage following intramuscular injection with PFFs were assessed for markers of mature αSyn inclusion pathology using antibodies directed towards αSyn at the N-terminus (2H6) and C-terminus (3H19), as well as sequestrasome-1 (p62). Sections were counterstained with hematoxylin. Scale bar = 100 μm. Figure S3: αSyn inclusion pathology was not detected in the CNS of PBS-injected APOE ε3+/+/M83+/− and APOE ε4+/+/M83+/− mice. Representative images of immunostaining from the spine and medulla of PBS-injected (a) APOE ε4+/+/M83+/− and (b) APOE ε3+/+/M83+/− mice. Tissue was analyzed with antibodies directed towards αSyn phosphorylated at Ser129 (81A), at the N-terminus (2H6) and C-terminus (3H19), as well as sequestrasome-1 (p62). Sections were counterstained with hematoxylin. Scale bar = 300 μm.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lloyd, G.M., Long, B., Quintin, S. et al. Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis. acta neuropathol commun 11, 119 (2023). https://doi.org/10.1186/s40478-023-01623-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40478-023-01623-9

Keywords

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us